|Page (1) of 1 - 12/11/17||email article||print page|
(December 11, 2017)
DGAP-News: MOLOGEN AG / Key word(s): Conference
PRESS RELEASE N 21 / 2017 of 11/12/2017
Poster Presentations on lefitolimod and EnanDIM(R) at
Berlin, 11 December 2017 - The biopharmaceutical company MOLOGEN AG (ISIN DE0006637200; Frankfurt Stock Exchange Prime Standard: MGN) presented two posters at the ESMO IO 2017 (European Society for Medical Oncology - Immuno Oncology) in Geneva, Switzerland (7 - 10 December 2017). The first poster featured data on patient characteristics from the pivotal IMPALA study in metastatic colorectal cancer (mCRC) evaluating the lead product candidate lefitolimod. IMPALA includes a representative mCRC patient group - a prerequisite to guide standard maintenance therapy in future. A second poster showed the impact of the EnanDIM(R) family of TLR9 agonists on the tumor microenvironment (TME) in murine models and the anti-tumor effect in combination with immune checkpoint inhibitors.
"We are delighted that the presentation on IMPALA has been well received and that our Steering Committee considers the maintenance treatment scheme with lefitolimod to have practice-changing potential - provided the outcome of IMPALA will be positive. In other words, lefitolimod could potentially be a safe and efficacious maintenance treatment after successful first line therapy. This would place MOLOGEN in a very attractive position in the CRC market - even in the light of other novel immune-oncology approaches", said Dr Matthias Baumann, CMO of MOLOGEN AG.
IMPALA: Representative mCRC study population
EnanDIM(R): High potential as single agent or in combination in immuno-oncology
Dr Mariola Söhngen, CEO of MOLOGEN AG: "We believe that patients can benefit from the combination of these immunotherapeutic approaches due to the fact that their modes of action complement each other. The EnanDIM(R) molecules initiate a broad activation of the innate and adaptive immune system and may achieve the conversion of "cold" into "hot" tumors which is a prerequisite for a response to checkpoint inhibitors."
The EnanDIM(R) molecules consist entirely of natural DNA, as is also the case with lefitolimod. The main difference between MOLOGEN's two ISR families is their molecule structure. Whereas lefitolimod is dumbbell-shaped and covalently-closed, EnanDIM(R) molecules have a linear structure. However, as with lefitolimod, due to its specific structure, no chemical modification is needed in order to protect the molecules against degradation by enzymes. The EnanDIM(R) molecules initiate a broad activation of the innate and adaptive immune system. The conversion of non-immunogenic ("cold") tumors into immunogenic ("hot") tumors, characterized by their T cell infiltration, is a prerequisite for a response to checkpoint inhibitors.
The study is conducted in collaboration with three renowned national study groups: Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany, Grupo Españiol de Tratamiento de Tumores Digestivos (TTD) in Spain and Groupe Coopérateur Multidisciplinaire en Oncologie (GERCOR) in France. The Steering Committee consists of internationally recognized medical experts including Prof. David Cunningham, MD, Department of Medicine and Director of Clinical Research, Royal Marsden Hospital, London, UK, as coordinating investigator.
For more information on the trials IMPACT and IMPALA please visit www.clinicaltrials.gov.
For more information on ESMO IO 2017 please visit the website